NCT05205967

REFLECTION: A Clinical Practice Learning Program for Galleri®

Active, enrolled Last updated 26 November 2025

What this trial tests

trial testing MCED in Early Detection of Cancer in 14,633 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 August 2021

Primary endpoint
30 September 2025

30 October 2026

Quick facts

Lead sponsor	GRAIL, Inc.
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	14,633
Start date	23 August 2021
Primary completion	30 September 2025
Estimated completion	30 October 2026
Sites	16 locations across United States

Drugs / interventions tested

• MCED
• SOC

Conditions studied

• Early Detection of Cancer — all drugs for Early Detection of Cancer →
• Cancer — all drugs for Cancer →

Sponsor

GRAIL, Inc. — full company profile →

Who can join

22 and older, any sex, with Early Detection of Cancer or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests.
   Brito-Rocha T, Constâncio V, Henrique R, Jerónimo C. · · 2023 · cited 72× · PMID 36980276 · DOI 10.3390/cells12060935
2. Emerging Tests for Noninvasive Colorectal Cancer Screening.
   Hanna M, Dey N, Grady WM. · · 2023 · cited 36× · PMID 36539002 · DOI 10.1016/j.cgh.2022.12.008
3. Screening for pancreatic cancer has the potential to save lives, but is it practical?
   Mazer BL, Lee JW, Roberts NJ, Chu LC, et al · · 2023 · cited 23× · PMID 37212770 · DOI 10.1080/17474124.2023.2217354
4. Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
   Imai M, Nakamura Y, Yoshino T. · · 2025 · cited 15× · PMID 39799530 · DOI 10.1007/s10147-025-02694-5
5. Brave new world of cfDNA-omics for early cancer detection.
   Rolfo C, Russo A. · · 2023 · cited 11× · PMID 37696620 · DOI 10.1136/jitc-2022-006309
6. Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening.
   Galeș LN, Păun MA, Anghel RM, Trifănescu OG. · · 2024 · cited 9× · PMID 38539525 · DOI 10.3390/cancers16061191
7. Innovative approaches in colorectal cancer screening: advances in detection methods and the role of artificial intelligence.
   Duan C, Sheng J, Ma X. · · 2025 · cited 5× · PMID 39898356 · DOI 10.1177/17562848251314829
8. Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation.
   Xu Y, Zhu S, Xia C, Yu H, et al · · 2025 · cited 2× · PMID 40670203 · DOI 10.1016/j.scib.2025.06.030